5 Design Change Considerations to Stay Compliant

Thursday, June 6, 2019 · 1:30 p.m. - 3:00 p.m. EDT

Medical device design change is a demanding and uneasy process. Failure to dot all your i’s and cross all your t’s can lead to inspection problems on the downside and missed market opportunities on the upside.

FDA QSR §820.30(i) spells out the basics but 820.30(i) is only the starting place for you and the team. FDA’s QSIT tells investigators that production and process changes under §820.70 may also be design changes under §820.30(i). Also in play: 21 CFR §820.75 and ISO 13485:2016. It’s complicating your processes.

Here to straighten things out is Dan O’Leary, FDAnews’s expert on all things technical involving medical devices — and one of our most sought-after presenters. 

Webinar Takeaways:

  • Relationship among design output, design transfer and production control
  • Reason why the FDA may deem a production change to be a design change
  • Elements of the new UDI rule including the Device Identifier (DI)
  • Triggers that create a new DI and how to document your decision
  • Requirement to evaluate change significance for possible 510(k) submission
  • Use of the 510(k) change guidance documents
  • Changes to the risk management file resulting from a design change
  • Implications for FDA inspections

Special Bonus Materials: Checklists you will use to ensure effective implementation.

If your responsibilities include production and process changes, then you need to determine whether they are design changes and how to implement them. If they include design changes, then you need to understand all the considerations for a complete and compliant change and the associated records. And that’s exactly what you get when you check in with Dan O’Leary! Join us by registering today.

Who Will Benefit

Design change is usually a cross-function and multi-discipline team endeavor. Team members who should attend include:

  • Design Engineers
  • Manufacturing Engineers
  • Quality Engineers
  • Risk Managers
  • Quality/QSR
  • GMP and cGMP
  • Regulatory Affairs

Webinar plus USB Audio Recording/Transcript
Learn more

$487

add to cart

Webinar only
Learn more

$287

add to cart

24/7 Encore plus USB Audio Recording/Transcript
Learn more

$487

add to cart

24/7 Encore Presentation
Learn more

$287

add to cart

USB Audio Recording/Transcript
Learn more

$287

add to cart

 

Meet Your Presenter

Dan O’Leary

President
Ombu Enterprises LLC

Dan O’Leary, one of FDAnews’s most sought-after presenters, is President of Ombu Enterprises LLC, a company offering training and execution in Operational Excellence focusing on analytic skills and a systems approach to operations management. Mr. O’Leary has more than 30 years experience in quality, operations and program management in regulated industries including medical devices, clinical labs, aviation and defense. He is an ASQ certified Biomedical Auditor, Quality Auditor, Quality Engineer, Reliability Engineer, and Six Sigma Black Belt; and is certified by APICS in Resource Management.

MII logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.

Phone (703) 538-7600 | Fax (703) 538-7676 | Toll free (888) 838-5578 | Email customerservice@fdanews.com

© 2019 FDAnews